BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Merikhian P, Eisavand MR, Farahmand L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell Int 2021;21:419. [PMID: 34376211 DOI: 10.1186/s12935-021-02107-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. Expert Opinion on Investigational Drugs 2022. [DOI: 10.1080/13543784.2022.2151433] [Reference Citation Analysis]
2 Li Y, Liu R, Han X, Xu W, Liu Y. PLAGL2 increases adriamycin resistance and EMT in breast cancer cells by activating the Wnt pathway. Genes Genom 2022. [DOI: 10.1007/s13258-022-01330-0] [Reference Citation Analysis]
3 Ma K, Chen H, Wang K, Han X, Zhang Y, Wang H, Hu Z, Wang J. Pterostilbene inhibits the metastasis of TNBC via suppression of β-catenin-mediated epithelial to mesenchymal transition and stemness. Journal of Functional Foods 2022;96:105219. [DOI: 10.1016/j.jff.2022.105219] [Reference Citation Analysis]
4 Mahmoud R, Ordóñez-morán P, Allegrucci C. Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness. Cancers 2022;14:4280. [DOI: 10.3390/cancers14174280] [Reference Citation Analysis]
5 Kordias D, Kostara CE, Papadaki S, Verigos J, Bairaktari E, Magklara A. Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities. Cells 2022;11:2719. [DOI: 10.3390/cells11172719] [Reference Citation Analysis]
6 Arzi L, Mollaei H, Hoshyar R. Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach. Plants 2022;11:2191. [DOI: 10.3390/plants11172191] [Reference Citation Analysis]
7 Pouliquen DL, Boissard A, Henry C, Coqueret O, Guette C. Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies. Front Pharmacol 2022;13:934534. [DOI: 10.3389/fphar.2022.934534] [Reference Citation Analysis]
8 Hu X, Zhang Q, Xing W, Wang W. Role of microRNA/lncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer. Front Pharmacol 2022;13:814971. [DOI: 10.3389/fphar.2022.814971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 You W, Ma F, Zhang Z, Yan J. Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors. Pharmaceutics 2022;14:1306. [PMID: 35745877 DOI: 10.3390/pharmaceutics14061306] [Reference Citation Analysis]
10 Mohammadi A, Najafi S, Amini M, Mansoori B, Baghbanzadeh A, Hoheisel JD, Baradaran B. The potential of B7-H6 as a therapeutic target in cancer immunotherapy. Life Sci 2022;304:120709. [PMID: 35697295 DOI: 10.1016/j.lfs.2022.120709] [Reference Citation Analysis]
11 Cheng Z, Yu R, Li L, Mu J, Gong Y, Wu F, Liu Y, Zhou X, Zeng X, Wu Y, Sun R, Xiang T. Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis. Cell Mol Life Sci 2022;79:280. [PMID: 35507080 DOI: 10.1007/s00018-022-04295-1] [Reference Citation Analysis]
12 Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed 2022;3:8. [PMID: 35243562 DOI: 10.1186/s43556-022-00071-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Shi J, Zhang Y, Wang P, Nie Y, Ma Q. Luminous MoS2 nanosheet-based electrochemiluminescence biosensor with biomimetic vesicle for miRNA-210 detection. Talanta 2022;237:122969. [PMID: 34736693 DOI: 10.1016/j.talanta.2021.122969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
14 Samuels M, Cilibrasi C, Papanastasopoulos P, Giamas G. Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. Biomolecules 2022;12:132. [DOI: 10.3390/biom12010132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Suresh S, Huard S, Brisson A, Némati F, Dakroub R, Poulard C, Ye M, Martel E, Reyes C, Silvestre DC, Meseure D, Nicolas A, Gentien D, Fayyad-Kazan H, Le Romancer M, Decaudin D, Roman-Roman S, Dubois T. PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers (Basel) 2022;14:306. [PMID: 35053470 DOI: 10.3390/cancers14020306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Suresh S, Huard S, Brisson A, Némati F, Poulard C, Ye M, Martel E, Reyes C, Silvestre DC, Meseure D, Nicolas A, Gentien D, Le Romancer M, Decaudin D, Roman-roman S, Dubois T. PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer.. [DOI: 10.1101/2021.10.22.465320] [Reference Citation Analysis]